

Table 1. Detection of antiviral drug-resistant viruses in Japan during the 2025/2026 influenza season

as of June 2, 2026

	A(H1N1)pdm09						A(H3N2)						B				
	Baloxavir	Oseltamivir	Peramivir	Zanamivir	Laninamivir	Amantadine	Baloxavir	Oseltamivir	Peramivir	Zanamivir	Laninamivir	Amantadine	Baloxavir	Oseltamivir	Peramivir	Zanamivir	Laninamivir
<b>Resistant (%)</b>	0	1 (1.0%)	1 (1.0%)	0	0	55 (100%)	11 (1.1%)	0	0	0	0	314 (100%)	0	0	0	0	0
<b>Number of viruses tested</b>	79	96	96	49	49	55	994	289	289	289	289	314	347	98	98	98	98
<b>Number of viruses reported</b>	199						5,388						3,342				

Baloxavir was examined by focus reduction assay, rhPCR allelic discrimination and/or PA sequencing.

NA inhibitors were examined by fluorescence-based NA-Fluor assay, chemiluminescence-based NA-XTD assay, real time RT-PCR allelic discrimination and/or NA sequencing.

Amantadine was examined by M2 sequencing.